A PHASE IIB, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGE FINDING CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-3102 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AND INADEQUATE GLYCEMIC CONTRO

MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 22 人开始时间: 2011年2月25日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•Has type 2 diabetes mellitus and is between 18 and 70 years of age; for Japan, 20 to 70 years of age;
•Has a body mass index (BMI) > 20 kg/m^2 and < 43 kg/m^2; for Japan: BMI >18 kg/m^2 and <43 kg/m^2;
•Is currently not on an antihyperglycemic agent (AHA) medication (off for ≥ 14 weeks) or is on oral AHA therapy but has inadequate glycemic control;
•Is a male, or a female who is highly unlikely to conceive.

•Has a history of type 1 diabetes mellitus or a history of ketoacidosis;
•Is on a weight loss program or has started a weight loss medication within the prior 8 weeks;
•Has required insulin therapy within 14 weeks prior to signing informed consent;
•Has a medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic active hepatitis B or C, cirrhosis, or symptomatic gallbladder disease;
•Has congestive heart failure or has new or worsening signs or symptoms of coronary heart disease;
•Had any of the following disorders within the past 3 months: acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder;
•Has a history of malignancy or clinically important hematological disorder

发起方

MERCK SHARP & DOHME PERU S.R.L.,